Drug Trial Radar · NCT05279131
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
Last checked: Nov 20, 2026Latest source record: Jan 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jun 28, 2022
Primary completion
Dec 28, 2022
Study completion Dec 28, 2022
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- First posted
- Mar 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\^2 on the face or balding scalp.
Conditions
- Keratosis, Actinic
Interventions
Tirbanibulin ointment 1%Drug
Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 5Time frame: Baseline, Day 5
- Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 8Time frame: Baseline, Day 8
- Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 15Time frame: Baseline, Day 15
- Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 29Time frame: Baseline, Day 29
- Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 57Time frame: Baseline, Day 57
- Number of Participants With Maximum Local Tolerability Score Post-baseline for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration)Time frame: Baseline, Maximum post-baseline (up to Day 57)
- Time to Maximum Local Tolerability Score for Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/UlcerationTime frame: Baseline up to Day 57
- Local Tolerability Signs Total Composite Score by Visit at Day 5Time frame: Baseline, Day 5
- Local Tolerability Signs Total Composite Score by Visit at Day 8Time frame: Baseline, Day 8
- Local Tolerability Signs Total Composite Score by Visit at Day 15Time frame: Baseline, Day 15
- Local Tolerability Signs Total Composite Score by Visit at Day 29Time frame: Baseline, Day 29
- Local Tolerability Signs Total Composite Score by Visit at Day 57Time frame: Baseline, Day 57
- Maximum Local Tolerability Signs Total Composite Score Post BaselineTime frame: Baseline, Maximum post-baseline (up to Day 57)
- Time to Maximum Local Tolerability Total Composite ScoreTime frame: Baseline up to Day 57
- Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 5Time frame: Baseline, Day 5
- Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 8Time frame: Baseline, Day 8
- Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 15Time frame: Baseline, Day 15
- Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 29Time frame: Baseline, Day 29
- Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 57Time frame: Baseline, Day 57
- Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)Time frame: Baseline up to Day 57
- Number of Participants With Clinically Significant Abnormalities in Laboratory ParametersTime frame: Baseline up to Day 57
- Number of Participants With Clinically Significant Abnormalities in Vital SignsTime frame: Baseline up to Day 57
- Number of Participants With Clinically Significant Abnormalities in Physical ExaminationTime frame: Baseline up to Day 57
- Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)Time frame: Baseline up to Day 57
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Almirall Investigation Site 7
Hot Springs, Arkansas
Almirall Investigation Site 6
Encinitas, California
Almirall Investigation Site 3
Sweetwater, Florida
Almirall Investigation Site 5
Rolling Meadows, Illinois
Almirall Investigation Site 4
Austin, Texas
Almirall Investigational Site 1
College Station, Texas
Almirall Investigation Site 2
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.